Lakewood, Colorado – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, believes the future of medicine begins with a single drop of blood. From lifesaving blood transfusions to novel personalized therapies, blood and cells are the foundation of healthcare innovation. In an interview as part of the Acumen Media Film Series DAVOS Interviews 2025, available on CBSnews.com, CEO Antoinette Gawin discusses how the company is pioneering this transformation.
"Terumo BCT is dedicated to unlocking the potential of blood and cells to improve patient outcomes and address critical medical needs," says Antoinette Gawin, President and CEO, Terumo BCT. "If you've ever donated blood or benefited from a blood transfusion or stem cell transplant, you've likely interacted with our technologies."
Building on its legacy of innovation, Terumo BCT provides an ecosystem of technologies, services, and solutions that enhance the efficiency and quality of blood collection and processing. From plasma-derived therapies to groundbreaking cell and gene therapies, the company's solutions are enabling and expanding the role of blood as a vital tool in personalized medicine.
Terumo BCT's commitment to expanding access to care includes overcoming the critical challenge of ensuring a safe and sustainable blood supply. As Gawin explains, "Blood cannot be manufactured, but it is the foundation of a resilient healthcare system. Removing barriers to a reliable blood supply is essential to improving patient care, especially when challenges like access delays can directly affect outcomes."
Through end-to-end partnerships with industry leaders, governments, and patient advocacy groups, Terumo BCT is driving patient-centered solutions. From policy and reimbursement strategies to education and advocacy, the company works globally to ensure that innovations in blood and cell therapies reach those who need them most.
"When you work together, you can achieve remarkable outcomes," adds Gawin. "For example, one of our priorities is driving transformative change in sickle cell disease treatment worldwide. In the UK, we're partnering with the National Health Service (NHS) to improve access to cost-effective technologies that improve patient outcomes through the MedTech Funding Mandate. In the United States, the company is working with the National Alliance of Sickle Cell Centers (NASCC) to raise awareness and increase access to blood therapies like red blood cell exchange."
"At Terumo BCT, we're transforming hope into reality — one patient, one innovation, one solution at a time," says Gawin. "Every drop of blood holds the potential to save lives."
To learn more about how the company is unlocking the potential of blood and cells to transform healthcare, viewers are invited to watch CEO Antoinette Gawin's interview in the DAVOS Interviews 2025 on CBSnews.com.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. www.terumobct.com